CYTOGEN ANNOUNCES APPOINTMENT OF JOHN E. BAGALAY, JR.
          AS INTERIM CHIEF FINANCIAL OFFICER  



PRINCETON, N.J., October 29, 1997  --  CYTOGEN Corporation
(NASDAQ:CYTO) today announced the appointment of John E. Bagalay,
Jr. as interim Chief Financial Officer of the Company.  Dr.
Bagalay's appointment to this position will be in addition to his
existing role as Director.

In his capacity as Chief Financial Officer, Dr. Bagalay will
oversee the financial and investment functions of the Company. 
Since September, 1989, Dr. Bagalay has served as Managing
Director of Community Technology Fund, the venture capital
affiliate of Boston University.  Dr. Bagalay has been a member of
the CYTOGEN Board of Directors since October 1995, and currently
serves on the boards of directors of Seragen, Inc., Wave Systems
Corporation and several privately-held companies in the
biotechnology industry.  Dr. Bagalay holds a B.A. in Politics,
Philosophy and Economics, a Ph.D. in Political Philosophy from
Yale University, and a J.D. from the University of Texas.

Thomas J. McKearn, President, Chief Executive Officer and
Chairman of CYTOGEN stated, "Dr. Bagalay's appointment as Chief
Financial Officer follows the departure of T.J. Madison from this
position.  Mr. Madison has left CYTOGEN and its subsidiaries
because of differences over the business strategies of the
Company and will return to pursuing interests in venture capital
and investment banking."  

CYTOGEN is a biopharmaceutical company engaged in the development, 
manufacture, and commercialization of products for the targeted delivery 
of diagnostic and therapeutic substances directly to disease sites.  
CYTOGEN has demonstrated its ability to develop new technology from early 
discovery through clinical development, regulatory approval and
commercial-scale biologic manufacturing.